Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-02-04Clinical Trial Update: Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies [Phase 1]
Phase 1 VENOM trial evaluating venetoclax with obinutuzumab and magrolimab in relapsed and refractory indolent B-cell malignancies has compl…
-
CLINICAL_TRIALS trial_result · 2025-01-16Clinical Trial Update: Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) [Phase 2]
Phase 2 trial evaluating acalabrutinib in patients with chronic lymphocytic leukemia and mantle cell lymphoma after allogeneic stem cell tra…
-
CLINICAL_TRIALS trial_result · 2025-01-14Clinical Trial Update: Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma [Phase 2]
A Phase 2 study evaluating venetoclax in combination with ibrutinib in adult Japanese participants with relapsed/refractory mantle cell lymp…
-
CLINICAL_TRIALS trial_result · 2025-01-13Clinical Trial Update: A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
This Phase 2 trial evaluates ibrutinib in combination with rituximab for relapsed or refractory mantle cell lymphoma. The study has complete…
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors [Phase 1, Phase 2]
An update on the Phase 1/2 study of CYT-0851 in B-cell malignancies and advanced solid tumors, noting completion of Phase 1/2 cohorts.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-12-16Clinical Trial Update: Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
A Phase 2 study evaluating ixazomib in combination with rituximab for relapsed or refractory mantle cell lymphoma was terminated, with resul…
-
CLINICAL_TRIALS trial_result · 2024-12-11Clinical Trial Update: TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 1]
Phase 1 trial evaluating SD-101 (TLR9 agonist) and BMS-986178 (anti-OX40 antibody) with radiation therapy for low-grade B-cell non-Hodgkin l…
-
CLINICAL_TRIALS trial_result · 2024-11-22Clinical Trial Update: Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma [Phase 4]
Phase 4 clinical trial update: acalabrutinib in Indian patients with chronic lymphocytic leukemia and relapsed/refractory mantle cell lympho…
-
CLINICAL_TRIALS trial_result · 2024-11-18Clinical Trial Update: Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating a combination of tafasitamab, lenalidomide and venetoclax for relapsed or refractory mantle cell lymphoma …
-
CLINICAL_TRIALS trial_result · 2024-11-15Clinical Trial Update: APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) [Phase 1, Phase 2]
A Phase 1/Phase 2 trial of APR-246 in combination with acalabrutinib or venetoclax in relapsed/refractory non-Hodgkin lymphoma has been term…
-
CLINICAL_TRIALS trial_result · 2024-10-24Clinical Trial Update: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 trial of bendamustine plus obinutuzumab induction with obinutuzumab maintenance in untreated mantle cell lymphoma; the study is term…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating SD-101 (TLR9 agonist) combined with Ibrutinib and radiation therapy in relapsed or refractory follicular lympho…
-
CLINICAL_TRIALS trial_result · 2024-09-23Clinical Trial Update: Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
Pfizer-sponsored STAR-TOR registry study update reports completion and posted results for a three-drug regimen of temsirolimus, sunitinib, a…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
Phase 2 study of a four-drug regimen (polatuzumab vedotin, venetoclax, rituximab, and hyaluronidase) in relapsed or refractory mantle cell l…
-
CLINICAL_TRIALS trial_result · 2024-08-30Clinical Trial Update: Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial from Memorial Sloan Kettering tested sequential chemotherapy and lenalidomide followed by rituximab and lenalidomid…
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab [Phase 3]
A Phase 3 randomized trial comparing bendamustine plus rituximab versus fludarabine plus rituximab in non-Hodgkin's lymphoma and mantle cell…
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) [Phase 1]
The ENABLE-1 Phase 1 trial investigates Toll-like receptor signaling to enhance B-cell lymphoma CAR-T therapy, with the study currently list…
-
CLINICAL_TRIALS trial_result · 2024-08-20Clinical Trial Update: CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies [Phase 1]
Phase 1 trial update for CLBR001 and SWI019 in relapsed/refractory B-cell malignancies has completed enrollment in a study targeting multipl…
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]
First-in-human study of GEN3009 in relapsed or refractory B-cell non-Hodgkin lymphomas was terminated, with results posted thereafter.
-
CLINICAL_TRIALS trial_result · 2024-08-12Clinical Trial Update: Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma [Phase 2]
Phase 2 trial at Peter MacCallum Cancer Centre is evaluating a venetoclax-ibrutinib-rituximab regimen with optional navitoclax for relapsed/…
-
CLINICAL_TRIALS trial_result · 2024-08-09Clinical Trial Update: Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma [Phase 2]
Phase 2 study evaluating a regimen of obinutuzumab, zanubrutinib, and lenalidomide, followed by a short cycle of obinutuzumab and cytarabine…
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 [Phase 2]
This Phase 2 trial update reports long-term follow-up data and thalidomide maintenance outcomes for patients enrolled in Clinical Trial 2003…
-
CLINICAL_TRIALS trial_result · 2024-07-31Clinical Trial Update: Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 study assessing TG-1801 alone or with ublituximab in patients with CLL, SLL, and other B-cell lymphomas was terminated.
-
CLINICAL_TRIALS trial_result · 2024-07-24Clinical Trial Update: A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/Phase 2 study evaluating Imvotamab monotherapy and in combination for relapsed/refractory non-Hodgkin lymphoma has been terminated…
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL [Phase 1, Phase 2]
Mustang Bio's MB-106 study in relapsed or refractory B-cell lymphomas and chronic lymphocytic leukemia has been terminated, covering Phase 1…